
WHAT IS CLAIMED IS:

1. A compound of Formula (**I-b-4**):



Formula (**I-b-4**)

or a pharmaceutically acceptable salt thereof, wherein:

$\mathbf{E^1}$ is $C\mathbf{R^{2a}}$;

$\mathbf{R^{2a}}$ and $\mathbf{R^{2b}}$ are each independently selected from the group consisting of: H and F;

$-(\mathbf{X^3})_{\mathbf{m3}}\text{-}\mathbf{R^1}$ is $C_{1\text{-}3}$ alkyl;

$\mathbf{X^a}$ is N;

$\mathbf{R^6}$ is F or Cl;

m4 and **m5** are independently 0, 1, or 2;

each $\mathbf{R^{a4}}$ and $\mathbf{R^{a5}}$ is independently selected from the group consisting of: F, CN, $C_{1\text{-}3}$ alkoxy, OH, and $C_{1\text{-}3}$ alkyl optionally substituted with 1-3 F;

$\mathbf{L^{A1}}$ is CH_2; and






$\mathbf{R^{Ya}}$ is $C_{1\text{-}3}$ alkyl optionally substituted with 1-3 F.

2. The compound of claim 1, wherein $\mathbf{R^{2b}}$ is H.

3. The compound of claim 1, wherein $\mathbf{R^{2b}}$ is F.

4. The compound of any one of claims 1-3, wherein **m4** is 0; and **m5** is 0.

5. The compound of any one of claims 1-3, wherein **m4** is 1 or 2; and **m5** is 0.

6. The compound of claim 5, wherein the  moiety is  ; or the  moiety is  or  .

7. The compound of any one of claims 1-3 or 5-6, wherein each $\mathbf{R^{a4}}$ is independently selected from the group consisting of: F and C_{1-3} alkyl optionally substituted with 1-3 F.


8. The compound of claim 7, wherein each $\mathbf{R^{a4}}$ is independently F or methyl.


9. The compound of any one of claims 1-8, wherein $\mathbf{R^{Ya}}$ is C_{1-3} alkyl; or $\mathbf{R^{Ya}}$ is methyl.


10. The compound of any one of claims 1-9, wherein $\mathbf{R^6}$ is Cl.


11. The compound of any one of claims 1-10, wherein $-(\mathbf{X^3})_{m3}\text{-}\mathbf{R^1}$ is methyl.


12. The compound of claim 1, wherein the compound is selected from the group consisting of:



















































































or a pharmaceutically acceptable salt thereof.

13. A pharmaceutical composition comprising a compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

14. Use of a compound of any one of claims 1-12 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 13 in the manufacture of a medicament for treating a cancer.

15. The use of claim 14, wherein the cancer is a hematological cancer, breast cancer, gastrointestinal cancer, brain cancer, lung cancer, or a combination thereof.

16. The use of claim 14 or 15, wherein the cancer is a hematological cancer; or wherein the hematological cancer is a lymphoma; or
the hematological cancer is FL or a large B cell lymphoma; or
the hematological cancer is a large B cell lymphoma; or
the hematological cancer is FL; or
the hematological cancer is DLBCL; or
the hematological cancer is a peripheral T-cell lymphoma (PTCL).

17. The use of any one of claims 14-16, wherein the medicament is configured for administration in combination with an additional therapy or therapeutic agent.

18. The use of claim 17, wherein the additional therapy or therapeutic agent is a PI3K inhibitor, an Abl inhibitor, a BTK inhibitor, a JAK inhibitor, a BRaf inhibitor, a MEK

inhibitor, a BCL-2 inhibitor, a Bcl-X_L inhibitor, an XPO1 inhibitor, an inhibitor of the polycomb repressive complex 2 (PRC2), an immunomodulatory imide drug, anti-CD19 therapy, anti-CD20 therapy, anti-CD3 therapy, chemotherapy, or a combination thereof; or

the additional therapy or therapeutic agent is an inhibitor of the PRC2; or

the additional therapy or therapeutic agent is an EZH1/2 or EZH2 inhibitor.

19. A compound of any one of claims 1-12 for use in therapy.